abs365.txt	background		adults	living	with	human	immunodeficiency	virus	(hiv)	are	atincreased	risk	for	anal	and	oropharyngeal	cancer	caused	by	papillomavirus(hpv)	the	efficacy	of	hpv	vaccines	in	this	population	is	unknown	methods	phase	3	double-blind	randomized	controlled	trial	we	assignedhiv-infected	aged	â‰¥27	years	to	quadrivalent	(types	6	11	16	18)vaccine	or	placebo	(1	1)	stratified	sex	presence	high-gradesquamous	intraepithelial	lesions	on	biopsy	(bhsil)	primary	endpoint	wasvaccine	against	incident	persistent	infection	quadrivalentvaccine	types	single	detection	at	final	visit	that	were	not	present	atbaseline	secondary	endpoints	included	vaccine	bhsil	after	week52	oral	results	a	total	575	participants	data	safetymonitoring	board	stopped	study	early	due	futility	was22%	(95	1%	confidence	interval	[ci]	-31%	53%)	prevention	analinfection	0%	(95%	ci	-44%	31%)	forimproving	outcomes	88%	2%	98%)	preventing	persistentoral	but	was	32%	-80%	74%)	6-month	oralhpv	conclusions	these	do	support	vaccination	hiv-infected	adultsaged	prevent	new	infections	improve	hsiloutcomes	however	our	suggest	role	finding	should	be	confirmed	future	studies	clinical	trials	registration	nct01461096
